Brought to you by

Warner Chilcott gets US rights to Novartis' Enablex
30 Sep 2010
Executive Summary
Novartis AG has granted Warner Chilcott PLC (primarily dermatology, women's health, gastrointestinal, and muscloskeletal conditions) exclusive US marketing rights to Enablex (darifenacin) extended-release tablets for adults with symptoms of an overactive bladder, which include urge urinary incontinence, urgency, and frequency.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com